Treatment with IL-6, on the other hand, presented a statistically significant enhancement in the migratory capacity of PLum-AD cells, with this increase reaching nearly 123% compared to the control (p-value < 0.01) (Fig 4C). This evidence concerns the gene IL6 and Alzheimer disease.